PTLF.US Petlife Pharmaceuticals Inc

Healthcare Pharmaceuticals USA Stocks
0.0001 USD
Close of Oct 11, 2026
0.0001 0.0002
Market cap
USD 19.7K
P/E
-
P/B
-
ROE
-
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Feb 2018.

Is PTLF.US undervalued?

Graham number

The Graham number of Petlife Pharmaceuticals Inc cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Petlife Pharmaceuticals Inc fundamental analysis

No fundamental analysis for Petlife Pharmaceuticals Inc yet.

Petlife Pharmaceuticals Inc stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Petlife Pharmaceuticals Inc

Petlife Pharmaceuticals, Inc. engages in the research, development, sale, and support of drugs and nutraceuticals for pet cancer and autoimmune related diseases, such as arthritis in the United States. The company's principal product is Vitalzul that inhibits blood vessels formation in solid tumors. It is also developing Vitalzul as a prescription strength oral pharmaceutical, as well as a concentrated intravenous and injectable version for direct administration to a tumor. …

Full company profile